Optimisation and validation of a high throughput screening compatible assay to identify inhibitors of the plasma membrane calcium ATPase pump - A novel therapeutic target for contraception and malaria

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 2, 2013, Pages 217-230

  Mohamed, Tamer M A ^a,b   Zakeri, Simon A ^a   Baudoin, Florence ^a   Wolf, Markus ^c   Oceandy, Delvac ^a   Cartwright, Elizabeth J ^a   Gul, Sheraz ^c   Neyses, Ludwig ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Zagazig University   (Egypt)

^c European ScreeningPort GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CARBOXYEOSIN; CONTRACEPTIVE AGENT; EGTAZIC ACID; ENZYME INHIBITOR; PLASMA MEMBRANE CALCIUM CALMODULIN DEPENDENT ADENOSINE TRIPHOSPHATASE 4; PLASMA MEMBRANE CALCIUM CALMODULIN DEPENDENT ADENOSINE TRIPHOSPHATASE 4 INHIBITOR; PLASMA MEMBRANE CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ANALYTICAL EQUIPMENT; ARTICLE; CONCENTRATION RESPONSE; CONTRACEPTION; CONTROLLED STUDY; DRUG SCREENING; ENZYME ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; MALARIA; MICROSOME; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; PROTEIN FOLDING; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

EID: 84878187914     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3pg68     Document Type: Article

References (43)

1. Sweadner KJ. Isozymes of the Na+/K+-ATPase. Biochim Biophys Acta. 1989;988:185-220.
2. Feraille E, Doucet A. Sodium-potassium adenosinetriphosphatase-dependent sodium transport in the kidney: hormonal control. Physiol Rev. 2001;81:345-418.
3. Glynn IM. A hundred years of sodium pumping. Annu Rev Physiol. 2002;64:1-18.
4. Rabon EC, Reuben MA. The mechanism and structure of the gastric H,K-ATPase. Annu Rev Physiol. 1990;52:321-44.
5. Mercadier J, Lompre A, Duc P, Boheler K, Fraysse J, Wisnewsky C, et al. Altered sarcoplasmic reticulum Ca2 (+)-ATPase gene expression in the human ventricle during end stage heart failure. The Journal of Clinical Investigation. 1990;85:305-9.
6. Overend CL, Eisner DA, O'Neill SC. Altered cardiac sarcoplasmic reticulum function of intact myocytes of rat ventricle during metabolic inhibition. Circulation Research. 2001;88:181-7.
7. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proceedings of the National Academy of Sciences. 2000;97:793-8.
8. Monte Fd, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308-11.
9. Monte Fd, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation. 2001;104:1424-9.
10. Oceandy D, Stanley P, Cartwright E, Neyses L. The regulatory function of plasma-membrane Ca (2+)-ATPase (PMCA) in the heart. Biochemical Society Transactions. 2007;35:927-30.
11. Cartwright EJ, Oceandy D, Austin C, Neyses L. Ca 2+ signalling in cardiovascular disease: the role of the plasma membrane calcium pumps. Science China Life Sciences. 2011;54:691-8.
12. Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban HJ, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet. 2009;41:527-34.
13. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677-87.
14. Kobayashi Y, Hirawa N, Tabara Y, Muraoka H, Fujita M, Miyazaki N, et al. Mice lacking hypertension candidate gene ATP2B1 in vascular smooth muscle cells show significant blood pressure elevation. Hypertension. 2012;59:854-60.
15. Tabara Y, Kohara K, Kita Y, Hirawa N, Katsuya T, Ohkubo T, et al. Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: the Japanese Millennium Genome Project. Hypertension. 2010;56:973-80.
16. Street VA, McKee-Johnson JW, Fonseca RC, Tempel BL, Noben-Trauth K. Mutations in a plasma membrane Ca2+-ATPase gene cause deafness in deafwaddler mice. Nature Genetics. 1998;19:390-4.
17. Schultz JM, Yang Y, Caride AJ, Filoteo AG, Penheiter AR, Lagziel A, et al. Modification of human hearing loss by plasma-membrane calcium pump PMCA2. New England Journal of Medicine. 2005;352:1557-64.
18. Kozel PJ, Friedman RA, Erway LC, Yamoah EN, Liu LH, Riddle T, et al. Balance and hearing deficits in mice with a null mutation in the gene encoding plasma membrane Ca2+-ATPase isoform 2. Journal of Biological Chemistry. 1998;273:18693-6.
19. Greeb J, Shull GE. Molecular cloning of a third isoform of the calmodulin-sensitive plasma membrane Ca2+-transporting ATPase that is expressed predominantly in brain and skeletal muscle. Journal of Biological Chemistry. 1989;264:18569-76.
20. Stauffer TP, Guerini D, Carafoli E. Tissue distribution of the four gene products of the plasma membrane Ca pump. Journal of Biological Chemistry. 1995;270:12184-90.
21. Kamagate A, Herchuelz A, Bollen A, Eylen FV. Expression of multiple plasma membrane Ca2+ ATPases in rat pancreatic islet cells. Cell Calcium. 2000;27:231-46.
22. Zanni G, Cali T, Kalscheuer VM, Ottolini D, Barresi S, Lebrun N, et al. Mutation of plasma membrane Ca2+ ATPase isoform 3 in a family with X-linked congenital cerebellar ataxia impairs Ca2+ homeostasis. Proc Natl Acad Sci U S A. 2012;109:14514-9.
23. Schuh K, Cartwright EJ, Jankevics E, Bundschu K, Liebermann J, Williams JC, et al. Plasma membrane Ca2+ ATPase 4 is required for sperm motility and male fertility. J Biol Chem. 2004;279:28220-6.
24. Okunade GW, Miller ML, Pyne GJ, Sutliff RL, O'Connor KT, Neumann JC, et al. Targeted ablation of plasma membrane Ca2+-ATPase (PMCA) 1 and 4 indicates a major housekeeping function for PMCA1 and a critical role in hyperactivated sperm motility and male fertility for PMCA4. J Biol Chem. 2004;279:33742-50.
25. Timmann C, Thye T, Vens M, Evans J, May J, Ehmen C, et al. Genome-wide association study indicates two novel resistance loci for severe malaria. Nature. 2012;489:443-6.
26. Mohamed T, Baudoin-Stanley FM, Abou-Leisa R, Cartwright E, Neyses L, Oceandy D. Measurement of plasma membrane calcium-calmodulin dependent ATPase (PMCA) activity. Methods in Molecular Biology (Clifton, NJ). 2010;637:333-42.
27. Fabiato online tool. http://maxchelator.stanford.edu/downloads.htm
28. Fabiato A. [31] Computer programs for calculating total from specified free or free from specified total ionic concentrations in aqueous solutions containing multiple metals and ligands. In: Sidney Fleischer BF, editor. Methods in Enzymology: Academic Press; 1988. p. 378-417.
29. Gatto C, Milanick MA. Inhibition of the red blood cell calcium pump by eosin and other fluorescein analogues. American Journal of Physiology Cell Physiology. 1993;264:C1577-C86.
30. Gatto C, Hale CC, Xu W, Milanick MA. Eosin, a potent inhibitor of the plasma membrane Ca pump, does not inhibit the cardiac Na-Ca exchanger. Biochemistry. 1995;34:965-72.
31. Choi HS, Eisner DA. The role of sarcolemmal Ca2+-ATPase in the regulation of resting calcium concentration in rat ventricular myocytes. The Journal of Physiology. 1999;515 (Pt 1):109-18.
32. Jones J, Rodgers J, Heil M, May J, White L, Maddry JA, et al. High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds. Assay Drug Dev Technol. 2007;5:181-89.
33. Jeffery JA, Sharom JR, Fazekas M, Rudd P, Welchner E, Thauvette L, et al. An ATPase assay using scintillation proximity beads for high throughput screening or kinetic analysis. Analytical Biochemistry. 2002;304:55-62.
34. Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye Q-Z, Blagg BSJ. High-throughput screening for Hsp90 ATPase inhibitors. Bioorganic & Medicinal Chemistry Letters. 2006;16:3005-8.
35. Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, Aherne W. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Analytical Biochemistry. 2004;327:176-83.
36. Osborn KD, Zaidi A, Mandal A, Urbauer RJ, Johnson CK. Single-molecule dynamics of the calcium-dependent activation of plasma membrane Ca2+-ATPase by calmodulin. Biophys J. 2004;87:1892-9.
37. Mohamed TM, Baudoin-Stanley FM, Abou-Leisa R, Cartwright E, Neyses L, Oceandy D. Measurement of plasma membrane calcium calmodulin-dependent ATPase (PMCA) activity. Methods in molecular biology (Clifton, NJ. 2010;637:333-42.
38. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circulation Research. 1987;61:70-6.
39. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. Journal of Cardiac Failure. 2009;15:171-81.
40. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery. 2010;9:203-14.
41. Garber AM. An uncertain future for cardiovascular drug development? New England Journal of Medicine. 2009;360:1169-71.
42. Wang S, Lublin J. Pfizer plans to abandon heart drug development. Wall Street Journal. 2008.
43. Plump AS, Lum PY. Genomics and cardiovascular drug development. Journal of the American College of Cardiology. 2009;53:1089-100.